Fully automated CLIA analyzers from Matrix Labs

Matrix Labs established in 2012 and markets its products and solutions to hospitals, individual healthcare providers, independent clinics and laboratories with comprehensive healthcare products and solutions of CLIA, HPLC, POCT, biochemistry, hematology, urine, and feces. As a pioneer in the field, Matrix Labs constantly pursues technological innovations to offer superior clinical benefits at a affordable cost. At Matrix Labs, quality healthcare solutions is considered as a fundamental right and the vision is to make it available for the people of all classes. The operations are run by highly involved professionals and have continuously set new trends through product development and improve­ments. Its research and development team works with latest technologies and methodologies to introduce inno­vative and new products to reach the customer. The company is following inter­national standard recom­mended controls to ensure the quality of its manu­facturing products. The company strictly follow the QMS and certified products end-to-end. Well known for its innovative approach, reliability, fairness, and responsibility are of high value in its relationship with customers and employees. The company provide continuity, quality and customer care which are bench mark of its business. The company understand that every customer requirement is unique and they adopt flexible solutions that are tailored to meet the customer needs.

The company’s vision is to become a one of the leading in-vitro diagnostics organization in India and mission is to support the human kind to reduce the burden of the diseases through innovation and research.

Fully automated CLIA analyzers
AutoLumo (A1000, A2000, and A1860) is a fully automated chemiluminescence immunoassay (CLIA) analyzers based on microparticles platform, which is designed for both quantitative and qualitative detection of biomarkers related to various diseases and dysfunctions. A wide range of para­meters are available with includes routine and special parameters. It is meant for the diagnosis of thyroids, fertility, cardiac, prenatal screening, glycol-metabolism, bone metabolism, ToRCH, tumor markers, anemia, inflam­mation monitoring, kidney function, infectious like HIV, HBsAg, HCV, Syphilis, HEV-IgG and HEV-IgM, and dengue panel (NS1/IgG/IgM). It is a fully automated random-access analyzer with true stat facility for sample. The throughput is 100 tests/hour (A1000) to 200 tests/hour (A2000). 100 samples with continuous loading facility and 24 different reagents can be loaded at a time.

Dengue NS1/IgG/IgM on fully automated CLIA platform
Dengue is one of the fastest spreading mosquito-borne viral disease, affecting more than 100 million humans annually around the world. Dengue found in more than 100 countries also causes around 25,000 deaths annually. The incidence of dengue has increased dramatically over the past few decades. Aedes mosquitoes transmit the virus and are common in tropical and subtropical parts of the world. Dengue fever is mainly caused by any of four distinct serotypes (DENV 1-4) of single-stranded RNA viruses of the genus Flavivirus. Detection of antigen (NS1) and antibodies (IgM and IgG) is the most widely used in diagnosis of dengue.

Matrix Labs provides first indigenous, fully automated chemiluminescence immuno­assay products for diagnosis of dengue. Dengue CLIA products are highly sensitive, ready-to-use reagents, and not required for any additional preparation procedure and sample dilution. Dengue CLIA products (NS1, IgM & IgG) are 30 min assay procedure and all the three products can be run simultaneously with other available routine parameters.

Key features:

• Microparticle-based fully automated;
• Detects NS1/IgM/IgG for all four serotypes;
• Highly sensitive;
• 12 months shelf life at 2-8 °C storage;
• Calibration stability – 28 days;
• Assay time – 30 min;
• No sample dilution;
• Dengue NS1 CLIA-Double antibody sandwich method;
• Dengue IgM CLIA-IgM capture method; and
• Dengue IgG CLIA-IgG capture method.